The pharmacological background of the antihypertensive activity and the side effects of urapidil, P.A. van Zwieten; antihypertensive and natriuretic effects of bunazosin on stroke-prone spontaneously hypertensive rats, M. Minami, et al; alpha1-andrenoceptor antagonists - studies on the sympathoinhibitory activity in anaesthetized rats, H. Togashi et al; primary prevention with metoprolol in hypertensive patients, J. Wikstrand; bopindolol - preclinical study and clinical correlations, T. Ishibashi and S. Imai; newly developed beta-blockers - basic and clinical investigations, K. Smimamoto and O. Iimura; clinical aspects of oral angiotensin converting enzyme inhibitors, M. Bursztyn and H. Gavras; molecular pharmacology of intracellular Ca2 antagonists, A. Nomura and H. Yasuda; pharmacology of central dopaminergic modulation in hypertension, M. van den Buuse and W. de Jong; serotonin-2 receptor antagonist - ketanserin, focus on the sympatoinhibitory action, M. Matsumoto, et al; basic and clinical pharmacology of fenoldopam and quinpirole, P. van der Niepen and A.G. Dupont; NTS neuronal mechanisms and clonidine action, T. Suga and M. Suzuki; centrally acting antihypertensive alpha-2 adrenoceptor agonists, G. Scholtsysik; indapamide as an antihypertensive agent, N. Toda; pharmacology of a new diuretic S-8666, M. Imai et al; budralazine - a direct-acting vasodilator, M. Yoskioka, et al; possible role of endothelium-derived nitric oxide in the regulation of blood pressure, I. Sakuma, et al; immunological factors in genetic hypertension, A. Bataillard, et al; pharmacokinetic properties of antihypertensive drugs, K. Miyazaki et al.
